EAMV: Set-Up of Medical Consumables Manufacturing Facility

EAMV is a state-of-the-art medical consumables plant that was operationalised in August 2021 and officially launched by the President of Uganda, H.E Yoweri Museveni on 11th December 2021.The company is the first medical consumables manufacturer in the East African region.

EAMV currently supplies National Medical Stores, the Ministry of Health, and Uganda Cancer Institute and the private market in Uganda. Regionally, the company has exported its gloves to South Sudan and Burundi.

ASIGMA has supported EAMV across the investment value chain, through preparation, fundraising and project development.

Objective

1. Prepare: EAMV shareholders came up with an idea to replace one of the components of the Maama kit. The Maama Kit is an urgent and cost-effective measure to ensure that childbirth is conducted in a clean environment. We then supported the shareholders to conduct a feasibility study including a market study, technical feasibility, and financial feasibility. The study led to the selection of medical consumables for the factory to produce and confirmed the feasibility of the project. Following the establishment of feasibility, a business plan was developed for selected medical consumables including situational analyses, entry points, financial planning and different business cases. A phased approach to the manufacturing of different consumables was opted for starting with medical gloves in the first phase.​
2. Fundraise: The documents developed in the preparation phase were then used to fundraise financing for the project. Additionally, a pitch deck to sell the idea to financiers was created and the team also provided transaction advisory support to ensure EAMV received the best available financing.
3. Develop and Manage: After financing was received, we supported EAMV through project management to establish the plant. This included project management for construction, human resource planning and management and reporting to financiers and shareholders.
4. Following construction of the plant, ASIGMA supported the operationalisation of the company. This included onboarding of technical consultants, application for licenses from the National Drug Authority, Uganda National Bureau of Standards among other regulatory bodies.

Outcome

1. Determined feasibility of the EAMV project. This included selection of medical consumables for the factory to produce.
2. Successful application to the Uganda Investment Authority for Investment License and obtaining investment land in Namanve Industrial Park.
3. Raising debt of USD 6.5 million.
4. Obtained construction and operating and manufacturing licenses from National Drug Authority, Uganda National Bureau of Standards and National Environment Management Authority among others.
5. Operationalisation and market entry of EAMV into the Ugandan and East African market.